Literature DB >> 17170138

p21 delays tumor onset by preservation of chromosomal stability.

Juan A Barboza1, Geng Liu, Zhenlin Ju, Adel K El-Naggar, Guillermina Lozano.   

Abstract

The p53 protein suppresses tumorigenesis by initiating cellular functions such as cell cycle arrest and apoptosis in response to DNA damage. A p53 mutant, p53R172P, which is deficient for apoptosis but retains a partial cell cycle arrest function, delays tumor onset in mice. Remarkably, lymphomas arising in Trp53(515C/515C) mice (encoding p53R172P) retain stable genomes. Given the dominant role of p21 in p53 cell cycle control, we crossed Trp53(515C/515C) mice onto a p21-null background to determine whether p21 was required for maintaining chromosomal stability and delaying tumor onset. Loss of p21 completely abolished the cell cycle arrest function of p53R172P and accelerated tumor onset in Trp53(515C/515C) mice. Cytogenetic examination of Trp53(515C/515C) p21(-/-) sarcomas and lymphomas revealed aneuploidy and chromosomal aberrations that were absent in Trp53(515C/515C) malignancies. Thus, p21 coupled p53-dependent checkpoint control and preservation of chromosomal stability, and cooperated with apoptosis in suppressing tumor onset in mice.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17170138      PMCID: PMC1702317          DOI: 10.1073/pnas.0606343104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  43 in total

1.  wt p53 dependent expression of a membrane-associated isoform of adenylate kinase.

Authors:  L Collavin; D Lazarevic; R Utrera; S Marzinotto; M Monte; C Schneider
Journal:  Oncogene       Date:  1999-10-21       Impact factor: 9.867

2.  The p53MH algorithm and its application in detecting p53-responsive genes.

Authors:  J Hoh; S Jin; T Parrado; J Edington; A J Levine; J Ott
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-19       Impact factor: 11.205

3.  Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis.

Authors:  X Xu; W Qiao; S P Linke; L Cao; W M Li; P A Furth; C C Harris; C X Deng
Journal:  Nat Genet       Date:  2001-07       Impact factor: 38.330

4.  A genomic map of p53 binding sites identifies novel p53 targets involved in an apoptotic network.

Authors:  Chaouki Miled; Marco Pontoglio; Serge Garbay; Moshe Yaniv; Jonathan B Weitzman
Journal:  Cancer Res       Date:  2005-06-15       Impact factor: 12.701

5.  Cdk4 disruption renders primary mouse cells resistant to oncogenic transformation, leading to Arf/p53-independent senescence.

Authors:  Xianghong Zou; Dipankar Ray; Aileen Aziyu; Konstantin Christov; Alexander D Boiko; Andrei V Gudkov; Hiroaki Kiyokawa
Journal:  Genes Dev       Date:  2002-11-15       Impact factor: 11.361

6.  Human wig-1, a p53 target gene that encodes a growth inhibitory zinc finger protein.

Authors:  F Hellborg; W Qian; C Mendez-Vidal; C Asker; M Kost-Alimova; M Wilhelm; S Imreh; K G Wiman
Journal:  Oncogene       Date:  2001-09-06       Impact factor: 9.867

7.  Functional collaboration between different cyclin-dependent kinase inhibitors suppresses tumor growth with distinct tissue specificity.

Authors:  D S Franklin; V L Godfrey; D A O'Brien; C Deng; Y Xiong
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

8.  Tumorigenic effect of nonfunctional p53 or p21 in mice mutant in the Werner syndrome helicase.

Authors:  M Lebel; R D Cardiff; P Leder
Journal:  Cancer Res       Date:  2001-03-01       Impact factor: 12.701

9.  Histone H2AX: a dosage-dependent suppressor of oncogenic translocations and tumors.

Authors:  Craig H Bassing; Heikyung Suh; David O Ferguson; Katrin F Chua; John Manis; Mark Eckersdorff; Megan Gleason; Rodrick Bronson; Charles Lee; Frederick W Alt
Journal:  Cell       Date:  2003-08-08       Impact factor: 41.582

10.  Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection.

Authors:  C Li; W H Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

View more
  50 in total

Review 1.  Mouse models of p53 functions.

Authors:  Guillermina Lozano
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-12-09       Impact factor: 10.005

Review 2.  p53 and regulation of bioactive sphingolipids.

Authors:  Linda A Heffernan-Stroud; Lina M Obeid
Journal:  Adv Enzyme Regul       Date:  2010-10-28

Review 3.  DNA repair pathways and their roles in drug resistance for lung adenocarcinoma.

Authors:  Altan Kara; Aykut Özgür; Sinem Nalbantoğlu; Abdullah Karadağ
Journal:  Mol Biol Rep       Date:  2021-04-15       Impact factor: 2.316

4.  Pla2g16 phospholipase mediates gain-of-function activities of mutant p53.

Authors:  Shunbin Xiong; Huolin Tu; Madhusudhan Kollareddy; Vinod Pant; Qin Li; Yun Zhang; James G Jackson; Young-Ah Suh; Ana C Elizondo-Fraire; Peirong Yang; Gilda Chau; Mehrnoosh Tashakori; Amanda R Wasylishen; Zhenlin Ju; Hilla Solomon; Varda Rotter; Bin Liu; Adel K El-Naggar; Lawrence A Donehower; Luis Alfonso Martinez; Guillermina Lozano
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-14       Impact factor: 11.205

5.  Anterior pituitary adenomas: inherited syndromes, novel genes and molecular pathways.

Authors:  Paraskevi Xekouki; Monalisa Azevedo; Constantine A Stratakis
Journal:  Expert Rev Endocrinol Metab       Date:  2010-09-01

Review 6.  The p53 target Wig-1: a regulator of mRNA stability and stem cell fate?

Authors:  A Vilborg; C Bersani; M T Wilhelm; K G Wiman
Journal:  Cell Death Differ       Date:  2011-03-11       Impact factor: 15.828

Review 7.  20 years studying p53 functions in genetically engineered mice.

Authors:  Lawrence A Donehower; Guillermina Lozano
Journal:  Nat Rev Cancer       Date:  2009-09-24       Impact factor: 60.716

Review 8.  p21 in cancer: intricate networks and multiple activities.

Authors:  Tarek Abbas; Anindya Dutta
Journal:  Nat Rev Cancer       Date:  2009-06       Impact factor: 60.716

9.  p21(Cip1) restrains pituitary tumor growth.

Authors:  Vera Chesnokova; Svetlana Zonis; Kalman Kovacs; Anat Ben-Shlomo; Kolja Wawrowsky; Serguei Bannykh; Shlomo Melmed
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-03       Impact factor: 11.205

10.  FATS is a transcriptional target of p53 and associated with antitumor activity.

Authors:  Xifeng Zhang; Qian Zhang; Jun Zhang; Li Qiu; Shuang-Shuang Yan; Juling Feng; Yan Sun; Xingxu Huang; Karen H Lu; Zheng Li
Journal:  Mol Cancer       Date:  2010-09-16       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.